Recently, Novo Nordisk announced the appointment of its new Chief Executive Officer, who outlined key strategic directions for the company’s future business expansion. In his inaugural address, the new CEO emphasized that Novo Nordisk will continue to focus on developing innovative therapies for chronic metabolic diseases such as obesity and diabetes, while accelerating its global footprint—particularly in high-growth markets like Asia and Latin America. He noted that with surging global demand for GLP-1-based medications (such as semaglutide), the company is actively scaling up production capacity and plans to enhance its supply chain through strategic partnerships and localized manufacturing. Additionally, the CEO highlighted increased investment in digital health and personalized medicine, exploring the integration of AI and big data into chronic disease management to improve patient experience and treatment adherence. He reaffirmed Novo Nordisk’s commitment to its core value of ‘patient-centricity,’ aiming to drive commercial growth while fulfilling its corporate social responsibility and contributing to global public health.
近日，诺和诺德（Novo Nordisk）宣布任命新任首席执行官，并就公司未来业务拓展方向作出重要阐述。新任CEO在就职演讲中强调，公司将持续聚焦于肥胖症与糖尿病等慢性代谢疾病的创新疗法研发，同时加速全球化布局，特别是在亚洲和拉丁美洲等高增长市场扩大影响力。他指出，随着全球对GLP-1类药物（如司美格鲁肽）需求激增，诺和诺德正积极提升产能以满足市场需求，并计划通过战略合作与本地化生产进一步优化供应链。此外，新任CEO还表示，公司将加大对数字健康和个性化医疗的投入，探索AI与大数据在慢病管理中的应用，以提升患者治疗体验和依从性。他重申，诺和诺德将继续秉持“以患者为中心”的核心价值观，在推动商业增长的同时，履行企业社会责任，助力全球公共健康事业的发展。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/16331.html